Navigation Links
Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
Date:5/9/2013

TORRANCE, Calif., May 9, 2013 /PRNewswire/ -- Timothy Cote , M.D., MPH, former director of the Office of Orphan Product Development of the U.S. Food and Drug Administration, has joined Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, in an advisory capacity, the company announced today.  Dr. Cote will advise Emmaus on the regulatory pathway for the company's sickle cell disease treatment.

"Dr. Cote's extensive regulatory knowledge and experience in rare diseases will be extremely beneficial as we move toward completion of our phase 3 clinical trial and into the analysis phase of the study," said Yutaka Niihara , M.D., MPH, founder and CEO of Emmaus Medical. "We remain on track to complete the study this year and look forward to working closely with Dr. Cote as we reach this important milestone, both for our company and the sickle cell disease community."

Dr. Cote is a leading national regulatory expert in orphan drug development. As a part of 22 years of federal service at the FDA, National Institutes of Health (NIH) and Centers for Disease Control (CDC), Dr. Cote served as the Director of the FDA Office of Orphan Products Development (OODP) from 2007 to 2011. The OODP is the FDA's primary interface with companies seeking orphan designation for drug and device products or seeking guidance in navigating FDA processes in reviewing orphan products.  Dr. Cote was instrumental in implementing the Orphan Drug Act and personally signed more than 800 orphan drug designations in his time at the Agency.

Dr. Cote also has served as Senior Federal Advisor to the Director, District of Columbia Department of Health; Branch Chief, Therapeutics and Blood Safety, FDA Center for Biologics Evaluation and Research (CBER); and Medical Director, Cancer Statistics Branch, National Cancer Institute. In 2011 Dr. Cote was the Chief Medical Officer for the National Organization for Rare Disorders (NORD). Currently, he is the Professor of Regulatory Practice at the Keck Graduate Institute in Claremont, California and principal of Cote Orphan Consulting.

"Finding a widely available treatment for sickle cell diseases is a clear priority and goes to the heart of the creation of Sickle Cell Disease Initiative, a program launched by the U.S. Department of Health and Human Services nearly two years ago," Dr. Cote said.  "I look forward to collaborating with Emmaus on potentially bringing forward this much needed treatment."

Emmaus' patent-protected treatment for Sickle Cell Anemia and β0-Thalassemia has Fast Track designation from the FDA, Orphan Drug designation in the United States and Orphan Medicinal Product designation in the European Union.

About Emmaus Medical, Inc.

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase 3 clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine products. For more information, please visit www.emmausmedical.com.

Contacts:

Media:
Lori Teranishi for Emmaus Medical, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:
Matt Sheldon for Emmaus Medical, Inc.
310-279-5975
msheldon@pondel.com


'/>"/>
SOURCE Emmaus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
2. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
3. Phonak and Special Olympics join forces with US Olympian, former Congressman Jim Ryun
4. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
5. Mike Golic, ESPN Radio Personality and Former Philadelphia Eagle, Holds Pre-Season "Training Camp" for People With Type 2 Diabetes
6. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
9. Prime Healthcare Hospitals Ranked as "Top Performers" by The Joint Commission
10. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
11. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family ... Pasco and Richland, is initiating a charity drive to support the family of ... recent automobile collision. , On October 29th of this year, Cindy Hendrickson ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
Breaking Medicine News(10 mins):